Optison

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
27-06-2022
Valmisteyhteenveto Valmisteyhteenveto (SPC)
27-06-2022

Aktiivinen ainesosa:

perflutren

Saatavilla:

GE Healthcare AS

ATC-koodi:

V08DA01

INN (Kansainvälinen yleisnimi):

perflutren

Terapeuttinen ryhmä:

Contrast media

Terapeuttinen alue:

Echocardiography

Käyttöaiheet:

This medicinal product is for diagnostic use only.Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.Optison should only be used in patients where the study without contrast enhancement is inconclusive.

Tuoteyhteenveto:

Revision: 19

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

1998-05-17

Pakkausseloste

                                16
B. PACKAGE LEAFLET
17 PACKAGE LEAFLET: INFORMATION FOR THE USER
OPTISON 0.19 MG/ML DISPERSION FOR INJECTION
Perflutren-containing microspheres
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What OPTISON is and what it is used for
2.
What you need to know before you use OPTISON
3.
How to use OPTISON
4.
Possible side effects
5.
How to store OPTISON
6.
Contents of the pack and other information
1.
WHAT OPTISON IS AND WHAT IT IS USED FOR
OPTISON is an ultrasound contrast agent that helps to obtain clearer
pictures (scan) of the heart during
an echocardiography (a procedure where an image of the heart is
obtained by using ultrasound).
OPTISON improves the visualization of the inner cardiac walls in
patients where the walls are
difficult to see.
OPTISON contains microspheres (tiny gas bubbles) that after injection
travel through the veins to the
heart and fill the left heart chambers, allowing the doctor to
visualise and asses the function of the heart.
This medicine is for diagnostic use only.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OPTISON
DO NOT USE OPTISON
-
if you are allergic (hypersensitive) to perflutren or any of the other
ingredients of OPTISON (listed
in section 6).
-
i
f you have severe pulmonary hypertension (systolic pulmonary artery
pressure > 90 mm Hg).
WARNINGS AND PRECAUTIONS
Talk to your doctor before using OPTISON
-
if you have any known allergies
-
if you have a severe heart, lung, kidney or liver disease. The
experience of OPTISON in severely ill
patients is limited
-
if you have an artificial valve in your heart
-
if you have acute severe inflammation or sepsis
-
if you have a known blood clotting problem
Your heart activity and rhythm will be monitored wh
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
OPTISON 0.19 mg/ml dispersion for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
OPTISON consists of perflutren-containing microspheres of heat treated
human albumin, suspended in
human albumin solution, 1%.
Concentration: Perflutren-containing microspheres, 5-8 x 10
8
/ml with a mean diameter range of
2.5 - 4.5 µm.
The approximate amount of perflutren gas in each ml of OPTISON is 0.19
mg.
Excipient with known effect
Each ml contains 0.15 mmol (3.45 mg) of sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Dispersion for injection.
Clear solution with white microsphere layer on top.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
This medicinal product is for diagnostic use only.
OPTISON is a transpulmonary echocardiographic contrast agent for use
in patients with suspected or
established cardiovascular disease to provide opacification of cardiac
chambers, enhance left
ventricular endocardial border delineation with resulting improvement
in wall motion visualisation.
OPTISON should only be used in patients where the study without
contrast enhancement is
inconclusive.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
OPTISON should only be administered by physicians experienced in the
field of diagnostic ultrasound
imaging.
Before administering OPTISON, please see section 6.6 for instructions
for use/handling.
This medicinal product is intended for left ventricular opacification
after intravenous administration.
Ultrasound imaging must be performed during injection of OPTISON as
optimal contrast effect is
obtained immediately after administration.
Posology
The recommended dose is 0.5 ml - 3.0 ml per patient. A dose of 3.0 ml
is usually sufficient, but some
3
patients may need higher doses. The total dose should not exceed 8.7
ml per patient. The duration of
the useful imaging time is 2.5 - 4.5 minutes for a dose of 0.5 - 3.0
ml. OPTISON could be repeatedly
administered, however, the clinical experience
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto bulgaria 27-06-2022
Pakkausseloste Pakkausseloste espanja 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto espanja 27-06-2022
Pakkausseloste Pakkausseloste tšekki 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto tšekki 27-06-2022
Pakkausseloste Pakkausseloste tanska 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto tanska 27-06-2022
Pakkausseloste Pakkausseloste saksa 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto saksa 27-06-2022
Pakkausseloste Pakkausseloste viro 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto viro 27-06-2022
Pakkausseloste Pakkausseloste kreikka 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto kreikka 27-06-2022
Pakkausseloste Pakkausseloste ranska 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto ranska 27-06-2022
Pakkausseloste Pakkausseloste italia 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto italia 27-06-2022
Pakkausseloste Pakkausseloste latvia 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto latvia 27-06-2022
Pakkausseloste Pakkausseloste liettua 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto liettua 27-06-2022
Pakkausseloste Pakkausseloste unkari 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto unkari 27-06-2022
Pakkausseloste Pakkausseloste malta 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto malta 27-06-2022
Pakkausseloste Pakkausseloste hollanti 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto hollanti 27-06-2022
Pakkausseloste Pakkausseloste puola 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto puola 27-06-2022
Pakkausseloste Pakkausseloste portugali 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto portugali 27-06-2022
Pakkausseloste Pakkausseloste romania 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto romania 27-06-2022
Pakkausseloste Pakkausseloste slovakki 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto slovakki 27-06-2022
Pakkausseloste Pakkausseloste sloveeni 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto sloveeni 27-06-2022
Pakkausseloste Pakkausseloste suomi 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto suomi 27-06-2022
Pakkausseloste Pakkausseloste ruotsi 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto ruotsi 27-06-2022
Pakkausseloste Pakkausseloste norja 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto norja 27-06-2022
Pakkausseloste Pakkausseloste islanti 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto islanti 27-06-2022
Pakkausseloste Pakkausseloste kroatia 27-06-2022
Valmisteyhteenveto Valmisteyhteenveto kroatia 27-06-2022

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia